<SEC-DOCUMENT>0001104659-26-059041.txt : 20260512
<SEC-HEADER>0001104659-26-059041.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512083005
ACCESSION NUMBER:		0001104659-26-059041
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TriSalus Life Sciences, Inc.
		CENTRAL INDEX KEY:			0001826667
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				853009869
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91951
		FILM NUMBER:		26966004

	BUSINESS ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031
		BUSINESS PHONE:		415 336 8917

	MAIL ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedTech Acquisition Corp
		DATE OF NAME CHANGE:	20200930

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Utmost Group Plc
		CENTRAL INDEX KEY:			0002046077
		ORGANIZATION NAME:           	
		EIN:				616132186
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		SADDLERS' HOUSE 5TH FLOOR,
		STREET 2:		44 GUTTER LANE,
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0
		BUSINESS PHONE:		02038614361

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		SADDLERS' HOUSE 5TH FLOOR,
		STREET 2:		44 GUTTER LANE,
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Utmost Group Plc -->
          <cik>0002046077</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001826667</issuerCik>
        <issuerName>TriSalus Life Sciences, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>89680M101</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>6272 W. 91st Ave.</com:street1>
          <com:city>Westminster</com:city>
          <com:stateOrCountry>CO</com:stateOrCountry>
          <com:zipCode>80031</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Utmost Group PLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3503385.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3503385.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3503385.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.71</classPercent>
      <typeOfReportingPerson>IC</typeOfReportingPerson>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>FI</typeOfReportingPerson>
      <comments>On 31 March 2026, Utmost Group PLC held 3,503,385 units of TriSalus Life Sciences's common shares, representing 5.71% of the outstanding shares. Compared to 30 September 2025, the ownership of Utmost Group PLC in the company decreased by more than 1% as a result of an increase in outstanding shares of the company.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>TriSalus Life Sciences, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>6272 W. 91st Ave. Westminster, CO 80031</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Utmost Group PLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Saddlers' House 5th Floor, 44 Gutter Lane, London, United Kingdom, EC2V 6BR</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United Kingdom</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>IC</typeOfPersonFiling>
        <typeOfPersonFiling>HC</typeOfPersonFiling>
        <typeOfPersonFiling>FI</typeOfPersonFiling>
        <otherTypeOfPersonFiling>Insurance Company</otherTypeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>3,503,385 shares</amountBeneficiallyOwned>
        <classPercent>5.71%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>3,503,385</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>None</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>3,503,385</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>None</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>Utmost Luxembourg S.A. - 4, rue Lou Hemmer, L1748 Luxembourg, Luxembourg (Registration number: B37604)</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to (J) A non-U.S. institution that is the functional equivalent of any of the institutions listed in ??240.13d 1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institutio is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Utmost Group PLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Ian Maidens</signature>
        <title>Ian Maidens - Group CFO</title>
        <date>05/05/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
